NeuroOne Medical Technologies to Showcase Neurological Solutions at Key Industry Conferences

NeuroOne Medical Technologies Corporation, trading on Nasdaq as NMTC, has announced its participation in two significant medical industry conferences scheduled for December 2025. The medical technology company, which focuses on enhancing surgical care options and outcomes for patients with neurological disorders, will engage with healthcare professionals and industry experts at both events.

The company will first participate in the American Epilepsy Society 2025 Annual Meeting in Atlanta, Georgia, from December 5th through December 9th. This gathering brings together healthcare providers, scientists, advocates, industry representatives, and other professionals dedicated to improving outcomes for people living with epilepsy. Conference details and registration information are available at https://www.aesnet.org/meetings_events/annual_meeting.

Following the AES meeting, NeuroOne will attend the CNS Drug Delivery Summit in Boston, Massachusetts, from December 9th through 11th. This seventh annual summit will host more than 100 industry experts including neuroscientists, chemists, device engineers, conjugation scientists, DMPK experts, and delivery specialists. The event focuses on collaborative efforts to address the unique challenges in gaining access to the brain for therapeutic purposes. Additional conference information can be found at https://www.cnsdrugdelivery.com.

NeuroOne's conference participation reflects the company's commitment to advancing neurological care through innovative medical technologies. The company specializes in developing and commercializing minimally invasive, high-definition solutions for EEG recording, monitoring, ablation, drug delivery, and stimulation. These technologies target patients suffering from various neurological conditions including epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain resulting from failed back surgeries.

The implications of NeuroOne's involvement in these conferences extend beyond corporate visibility. For healthcare providers and patients, the company's technologies represent potential advancements in neurological treatment options that could improve patient outcomes while reducing procedural costs. The dual focus on epilepsy treatment and CNS drug delivery indicates NeuroOne's comprehensive approach to addressing complex neurological challenges through multiple therapeutic modalities.

Industry observers note that participation in specialized medical conferences allows companies like NeuroOne to demonstrate their latest innovations to key opinion leaders and potential collaborators. The AES meeting specifically targets epilepsy professionals, while the CNS Drug Delivery Summit focuses on the technical challenges of delivering therapeutics to the brain - both areas directly relevant to NeuroOne's product development pipeline. This strategic conference attendance may facilitate partnerships, clinical adoption, and further innovation in neurological care.

For the broader medical community, NeuroOne's technologies represent ongoing progress in addressing some of the most challenging neurological conditions. The company's work in EEG recording and monitoring, combined with ablation and stimulation capabilities, offers integrated solutions that could streamline treatment protocols and improve the precision of neurological interventions. As neurological disorders affect millions worldwide, advancements in treatment technologies carry significant public health implications.